Literature DB >> 27404557

Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening.

Ivana Pibiri1, Laura Lentini2, Marco Tutone1, Raffaella Melfi1, Andrea Pace3, Aldo Di Leonardo4.   

Abstract

Ataluren, also known as PTC124, is a 5-(fluorophenyl)-1,2,4-oxadiazolyl-benzoic acid suggested to suppress nonsense mutations by readthrough of premature stop codons in the mRNA. Potential interaction of PTC124 with mRNA has been recently studied by molecular dynamics simulations highlighting the importance of H-bonding and stacking π-π interactions. A series of non-acidic analogues of PTC124 were selected from a large database via a ligand-based virtual screening approach. Eight of them were synthesized and tested for their readthrough activity using the Fluc reporter harboring the UGA premature stop codon. The most active compound was further tested for suppression of the UGA nonsense mutation in the bronchial epithelial IB3.1 cell line carrying the W1282X mutation in the CFTR gene.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CFTR gene; Cystic fibrosis; Nonsense mutation; Oxadiazoles; PTCs readthrough

Mesh:

Substances:

Year:  2016        PMID: 27404557     DOI: 10.1016/j.ejmech.2016.06.048

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  11 in total

Review 1.  Shwachman-Diamond Syndrome: Molecular Mechanisms and Current Perspectives.

Authors:  Valentino Bezzerri; Marco Cipolli
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

2.  Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).

Authors:  Marco Tutone; Ivana Pibiri; Riccardo Perriera; Ambra Campofelice; Giulia Culletta; Raffaella Melfi; Andrea Pace; Anna Maria Almerico; Laura Lentini
Journal:  ACS Med Chem Lett       Date:  2020-02-18       Impact factor: 4.345

3.  A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.

Authors:  Darren M Hutt; Salvatore Loguercio; Alexandre Rosa Campos; William E Balch
Journal:  J Mol Biol       Date:  2018-06-18       Impact factor: 5.469

4.  Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study.

Authors:  Marco Tutone; Ivana Pibiri; Laura Lentini; Andrea Pace; Anna Maria Almerico
Journal:  ACS Med Chem Lett       Date:  2019-02-07       Impact factor: 4.345

5.  Investigating REPAIRv2 as a Tool to Edit CFTR mRNA with Premature Stop Codons.

Authors:  Raffaella Melfi; Patrizia Cancemi; Roberta Chiavetta; Viviana Barra; Laura Lentini; Aldo Di Leonardo
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

Review 6.  Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes.

Authors:  Valentino Bezzerri; Martina Api; Marisole Allegri; Benedetta Fabrizzi; Seth J Corey; Marco Cipolli
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

7.  Caffeine boosts Ataluren's readthrough activity.

Authors:  Laura Lentini; Raffaella Melfi; Patrizia Cancemi; Ivana Pibiri; Aldo Di Leonardo
Journal:  Heliyon       Date:  2019-06-21

Review 8.  CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.

Authors:  Miquéias Lopes-Pacheco
Journal:  Front Pharmacol       Date:  2016-09-05       Impact factor: 5.810

Review 9.  Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.

Authors:  Matthew D Strub; Paul B McCray
Journal:  Genes (Basel)       Date:  2020-05-13       Impact factor: 4.096

Review 10.  Screening Readthrough Compounds to Suppress Nonsense Mutations: Possible Application to β-Thalassemia.

Authors:  Monica Borgatti; Emiliano Altamura; Francesca Salvatori; Elisabetta D'Aversa; Nicola Altamura
Journal:  J Clin Med       Date:  2020-01-21       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.